Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Lee's Pharmaceutical (950 HK)
Watchlist
17
Analysis
Health Care
•
Hong Kong
Lee's Pharmaceutical Holdings Limited develops, manufactures and sells quality biopharmaceutical products that focus on combating cardiovascular diseases and viral sexually transmitted diseases.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Sciclone Pharmaceuticals
•
28 Mar 2024 22:13
SciClone Pharma (6600 HK): GL Capital’s Scheme Offer at HK$18.80
The offer price has been declared final. It is reasonable, aligning with the all-time high and the IPO price. This is a done deal.
Arun George
Follow
743 Views
Share
bullish
•
Sciclone Pharmaceuticals
•
19 Mar 2024 17:27
SciClone Pharma (6600 HK): Privatisation Déjà Vu All over Again?
A GL Capital-led consortium will likely once again lead the privatisation. An offer price at or slightly above the IPO price (HK$18.80) would be...
Arun George
Follow
333 Views
Share
bullish
•
Zhaoke Ophthalmology Pharmaceutical
•
16 Apr 2021 17:20
Zhaoke Ophthalmology IPO: Valuation Insights
Zhaoke has launched an HKEx IPO to raise net proceeds of $239m at the mid-point of the IPO price range of HK$15.38-16.80 per share. Overall, we...
Arun George
Follow
489 Views
Share
bullish
•
Zhaoke Ophthalmology Pharmaceutical
•
12 Apr 2021 18:57
Zhaoke Ophthalmology IPO Initiation: The Eyes Have It
Zhaoke is pre-marketing an HKEx IPO to raise $200 million, according to press reports. Overall, we believe that Zhaoke’s drug assets are attractive.
Arun George
Follow
346 Views
Share
bearish
•
Zhaoke Ophthalmology Pharmaceutical
•
06 Apr 2021 11:03
Zhaoke Ophthalmic (兆科眼科) Pre-IPO: Thoughts on Valuation
In this note, we provide a forecast on Zhaoke Ophthalmic's two core products CsA ophthalmic gel and the ZKY001 and an SOTP based valuation for the...
Ke Yan, CFA, FRM
Follow
412 Views
Share
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3
x